Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

03. Juni 2026 08:00 ET | Quelle: Lexicon Pharmaceuticals, Inc.

Lexicon to Present Data at the American Diabetes Association (ADA) 2026 Scientific Sessions

THE WOODLANDS, Texas, June 03, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that it will present data from clinical studies of sotagliflozin in Type 1...
17. April 2026 08:00 ET | Quelle: Lexicon Pharmaceuticals, Inc.

Lexicon to Present Data at the American Academy of Neurology (AAN) Annual Meeting

Oral presentation highlights additional data from PROGRESS Phase 2b study of pilavapadin supporting selection of 10mg as optimal dose for Phase 3 development in DPNP New data on spasticity further...
12. Januar 2026 07:30 ET | Quelle: Lexicon Pharmaceuticals, Inc.

Lexicon Pharmaceuticals Provides a Business and Pipeline Update at the 44th Annual J.P. Morgan Healthcare Conference

SONATA-HCM on track for enrollment completion in 2026 and topline data in 2027 $10 million milestone payment triggered from licensing agreement with Novo Nordisk for LX9851 Zynquista on...
06. November 2025 07:30 ET | Quelle: Lexicon Pharmaceuticals, Inc.

Lexicon Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides R&D Updates

Lexicon Pharmaceuticals reported third quarter 2025 financial results and provided an update on key corporate milestones and accomplishments.